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Abstract
Background: Radiofrequency radiation in the frequency range 30 kHz–300 GHz was evaluated to be Group 2B, i.e.
‘possibly’ carcinogenic to humans, by the International Agency for Research on Cancer (IARC) at WHO in May 2011.
Among the evaluated devices were mobile and cordless phones, since they emit radiofrequency electromagnetic
fields (RF-EMF). In addition to the brain, another organ, the thyroid gland, also receives high exposure. The incidence of
thyroid cancer is increasing in many countries, especially the papillary type that is the most radiosensitive type.
Methods: We used the Swedish Cancer Register to study the incidence of thyroid cancer during 1970–2013 using
joinpoint regression analysis.
Results: In women, the incidence increased statistically significantly during the whole study period; average annual
percentage change (AAPC) +1.19 % (95 % confidence interval (CI) +0.56, +1.83 %). Two joinpoints were detected, 1979
and 2001, with a high increase of the incidence during the last period 2001–2013 with an annual percentage change
(APC) of +5.34 % (95 % CI +3.93, +6.77 %). AAPC for all men during 1970–2013 was +0.77 % (95 % CI −0.03, +1.58 %).
One joinpoint was detected in 2005 with a statistically significant increase in incidence during 2005–2013; APC +7.56 %
(95 % CI +3.34, +11.96 %). Based on NORDCAN data, there was a statistically significant increase in the incidence of
thyroid cancer in the Nordic countries during the same time period. In both women and men a joinpoint
was detected in 2006. The incidence increased during 2006–2013 in women; APC +6.16 % (95 % CI +3.94,
+8.42 %) and in men; APC +6.84 % (95 % CI +3.69, +10.08 %), thus showing similar results as the Swedish
Cancer Register. Analyses based on data from the Cancer Register showed that the increasing trend in Sweden was
mainly caused by thyroid cancer of the papillary type.
Conclusions: We postulate that the whole increase cannot be attributed to better diagnostic procedures. Increasing
exposure to ionizing radiation, e.g. medical computed tomography (CT) scans, and to RF-EMF (non-ionizing radiation)
should be further studied. The design of our study does not permit conclusions regarding causality.
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Background
Thyroid cancer is a relatively rare cancer. In total, 157
men and 429 women were reported to the Swedish
Cancer Register in 2013, or 0.95 % of all cancer cases
[1]. It is two to three times more common in women,
although the proportion is affected by age and histo-
logic type [2]. Reproductive and hormonal factors
have been suggested to explain this gender difference
[3, 4]. Ionizing radiation was first suggested in the
late 1940s and early 1950s to be associated with an
increased risk for thyroid cancer [5, 6]. It is the only
well-established risk factor as shown for external
radiotherapy [7, 8], diagnostic X-ray investigations [9],
among A-bomb survivors in Hiroshima and Nagasaki [10]
and after the Chernobyl and Fukushima disasters [11–13].
Papillary thyroid cancer is the most common histo-
logic type and represents 60–70 % of all cancers. It has
the best prognosis with 10-year survival rates varying
between 60 and 95 % [14, 15]. The papillary type is also
the most common radiation induced thyroid cancer [16].
The follicular type occurs in about 20 % of all thyroid
cancer cases. The prognosis is somewhat worse than for
the papillary type [15, 17]. There is also a mixed
papillary-follicular type, usually classified as papillary
thyroid cancer. The medullary type represents 4–10 % of
all thyroid cancer cases and is usually sporadic or famil-
ial [18]. The anaplastic thyroid cancer is an aggressive
type representing about 10 % of all thyroid cancer cases.
It affects mainly elderly patients and the median survival
time has been reported to be in the range of 3 to
6 months [19, 20].
The generally good prognosis for survival makes stud-
ies on incident cases more preferable than using mortal-
ity data. The aim of this study was to use the Swedish
Cancer Register to study the incidence of thyroid cancer.
In the diagnostic procedure, histology and/or cytology
are usually included. Due to the anatomical localization
it is easy to get a specimen for examination. It is compul-
sory for all health care providers to report new diagnostic
cancer cases to the register and most pathology depart-
ments have routines for doing so. Thus, the Swedish
Cancer Register was used for this study based on official
data without any personal identification. Approval by the
ethical committee was not necessary.
Methods
Study design
The National Board of Health and Welfare administers
the Swedish Cancer Register which was started in 1958.
The basis for diagnosis can be clinical examination, hist-
ology/cytology, surgery, autopsy, or other examinations
such as computed tomography (CT)/magnetic resonance
imaging (MRI) or laboratory investigations. Incidence per
100,000 person-years, age-adjusted according to the world
population, was analyzed for the ICD-7 code 194, i.e.
thyroid cancer based on data in the Swedish Cancer
Register for the time period 1970–2013. This data is
available online (http://www.socialstyrelsen.se/statistik/
statistikdatabas/cancer).
To study the incidence of different types of thyroid
cancer, data was obtained from the Swedish Cancer
Register for the time period 1993–2013 (earlier data is
not available). Due to low numbers of cases with rare
types of thyroid cancer a wider age group was used for
the youngest group, 0–39 years instead of 0–19 and 20–
39 years as was used for thyroid cancer in total.
In addition we used NORDCAN to assess incidence
data (ICD-10 code C73 = thyroid cancer) for all Nordic
countries (available at http://www-dep.iarc.fr/NORDCAN/
english/frame.asp). This data (age-adjusted according to
the world population) was retrieved for the same time
period as from the Swedish Cancer Register, 1970 to 2013,
and included Sweden, Denmark, Finland, Norway and
Iceland.
Statistical methods
The NCI Joinpoint Regression Analysis program, version
4.1.1.1 was used to examine trends in age-standardized
incidence by fitting a model of 0–4 joinpoints using set-
tings in default mode [21]. When joinpoints were de-
tected, annual percentage change (APC) and 95 % CIs
were calculated for each linear segment. Average annual
percentage changes (AAPC) were also calculated for the
whole time period using the average of the APCs
weighted by the length of the segment.
Results
The Swedish Cancer Register
In women the incidence increased statistically signifi-
cantly during the whole study period 1970–2013;
AAPC +1.19 % (95 % CI +0.56, +1.83 %). Two joinpoints
were detected, 1979 and 2001; 1970–1979 APC +2.15 %
(95 % CI +0.05, +4.30 %); 1979–2001 APC −1.39 % (95 %
CI −1.96, −0.82 %); 2001–2013 APC +5.34 % (95 %
CI +3.93, +6.77 %), see Table 1. In the age group 0–19
years no joinpoint was found, but the incidence increased
throughout the period with an AAPC of +1.32 %
(95 % CI +0.41, +2.24 %). In the age group 20–39
years one joinpoint was detected in 2006, with a high
APC for the time period 2006–2013; +10.77 % (95 %
CI +5.75, +16.04 %). That age group also showed the high-
est AAPC for the whole study period; AAPC +2.27 %
(95 % CI +1.46, +3.09 %). For 40–59 year old women, one
joinpoint was found in 2001 with a statistically significant
increase in incidence during 2001–2013; APC +5.03 %
(95 % CI +2.02, +8.13 %). Women aged 60–79 years
showed a statistically significant increase in incidence dur-
ing 2004–2013; APC +6.90 % (95 % CI +3.71, +10.19 %).
Carlberg et al. BMC Cancer  (2016) 16:426 Page 2 of 15
Figure 1 shows the joinpoint regression analysis of the
age-standardized incidence of thyroid cancer (ICD-194)
per 100,000 in all women during 1970–2013. A sharp in-
crease is shown from 2001. For specific age groups, the
highest APC was found in the age group of 20–39 dur-
ing 2006–2013. Figure 2 shows the results for that age
group with a joinpoint in 2006.
Table 2 shows the results for men. The incidence
increased for all men during 1970–2013 with an AAPC
of +0.77 % (95 % CI −0.03, +1.58 %). One joinpoint was
detected in 2005 with a statistically significant increase
in incidence during 2005–2013; APC +7.56 % (95 % CI
+3.34, +11.96 %). Due to a low number of cases, no cal-
culations could be made for subjects aged 0–19 years. In
the age groups 20–39, 40–59 and 60–79 years the
incidence increased for the whole period, although the
AAPCs were not statistically significant. No joinpoint
was found for ages 20–39 years. In the age group 40–59
years one joinpoint was found in 2006 with a statistically
significant increase in incidence during 2006–2013;
APC +9.92 % (95 % CI +1.92, +18.54 %). In subjects
aged 60–79 years two joinpoints were found, 1980 and
2005. During 2005–2013 the APC was +8.41 % (95 %
CI +4.02, +12.98 %). For men aged 80+ years the inci-
dence decreased with a statistically significant AAPC
and no joinpoint was found. These latter results were
based on 390 cases.
Figure 3 shows the joinpoint regression analysis of the
age-standardized incidence of thyroid cancer (ICD-194)
per 100,000 in men with an increasing incidence from
Table 1 Joinpoint regression analysis of thyroid cancer incidence in women in the Swedish Cancer Register
ICD-7 Joinpoint location APC 1 (95 % CI) APC 2 (95 % CI) APC 3 (95 % CI) AAPC (95 % CI)
194
All women (n = 10,757) 1979; 2001 +2.15 (+0.05, +4.30) −1.39 (−1.96, −0.82) +5.34 (+3.93, +6.77) +1.19 (+0.56, +1.83)
0–19 years (n = 271) No joinpoint detected - - - +1.32 (+0.41, +2.24)
20–39 years (n = 2,325) 2006 +0.70 (+0.30, +1.10) +10.77 (+5.75, +16.04) - +2.27 (+1.46, +3.09)
40–59 years (n = 3,361) 2001 −0.98 (−1.67, −0.29) +5.03 (+2.02, +8.13) - +0.66 (−0.27, +1.59)
60–79 years (n = 3,556) 1974; 2004 +9.58 (−1.34, +21.70) −2.13 (−2.64, −1.62) +6.90 (+3.71, +10.19) +0.75 (−0.43, +1.94)
80+ years (n = 1,244) 1979; 1998 +2.14 (−2.33, +6.81) −4.22 (−5.72, −2.70) +0.71 (−1.35, +2.82) −1.21 (−2.51, +0.11)
Time period 1970–2013, ICD-7 code 194 (http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer)
APC annual percentage change (APC 1 time from 1970 to first joinpoint, APC 2 time from first joinpoint to 2013 or to second joinpoint, APC 3 time from second
joinpoint to 2013), AAPC average annual percentage change
Fig. 1 Joinpoint regression analysis of age-standardized incidence of thyroid cancer for women, all ages 1970–2013. Incidence per 100,000
inhabitants for ICD-7 code 194 according to the Swedish Cancer Register (http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer)
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2005. Figure 4 shows the results for men aged 40–59
years with a joinpoint in 2006.
Histopathological type
Trends in the age-standardized incidence for the time
period 1993–2013 were calculated based on data from
the Swedish Cancer Register. Due to no registered
cases for some years for the anaplastic and medullary
types no APC could be calculated. Incidence for the
follicular type increased in women with +1.65 %
(95 % CI −0.31, +3.64 %; n = 659), and in men with
an APC of +0.40 % (95 % CI −2.26, +3.12 %; n = 281). No
joinpoint was detected. The only statistically significant in-
crease was found in the age group 0–39 years in women,
APC +5.32 % (95 % CI +0.42, +10.46 %; n = 129). APC for
mixed thyroid cancer was calculated in women to +2.52 %
(95 % CI −0.62; +5.76 %; n = 232), and in men to +6.04 %
(95 % CI +0.03, +12.41 %; n = 80). No joinpoint was
detected. APC for different age groups could not be calcu-
lated since no cases were registered for certain years.
Regarding papillary thyroid cancer the incidence in-
creased statistically significantly in women with an
AAPC of +4.38 % (95 % CI +2.95, +5.84 %; n = 3,439).
One joinpoint was detected in 2006; 1993–2006 APC
+1.69 % (95 % CI +0.32, +3.08 %), 2006–2013 APC
+9.58 % (95 % CI +5.85, +13.44 %), see Fig. 5. The inci-
dence increased in men during 1993–2013 with an APC
of +3.95 % (95 % CI +2.20, +5.73 %; n = 1,188). No join-
point was detected, see Fig. 6. In the analyses of different
age groups for women aged 0–39 years one joinpoint
Fig. 2 Joinpoint regression analysis of age-standardized incidence of thyroid cancer for women, aged 20–39 years 1970–2013. Incidence per
100,000 inhabitants for ICD-7 code 194 according to the Swedish Cancer Register (http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer)
Table 2 Joinpoint regression analysis of thyroid cancer incidence in men in the Swedish Cancer Register
ICD-7 Joinpoint location APC 1 (95 % CI) APC 2 (95 % CI) APC 3 (95 % CI) AAPC (95 % CI)
194
All men (n = 4,234) 2005 −0.72 (−1.15, −0.29) +7.56 (+3.34, +11.96) - +0.77 (−0.03, +1.58)
0–19 years (n = 76) - - - - -
20–39 years (n = 651) No joinpoint detected - - - +0.92 (−0.10, +1.94)
40–59 years (n = 1,271) 2006 −0.55 (−1.18, −0.09) +9.92 (+1.92, +18.54) - +1.08 (−0.22, +2.41)
60–79 years (n = 1,846) 1980; 2005 +2.33 (−0.64, +5.40) −2.14 (−2.91, −1.36) +8.41 (+4.02, +12.98) +0.79 (−0.31, +1.89)
80+ years (n = 390) No joinpoint detected - - - −2.21 (−3.55, −0.85)
Time period 1970–2013, ICD-7 code 194 (http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer)
APC annual percentage change (APC 1 time from 1970 to first joinpoint, APC 2 time from first joinpoint to 2013 or to second joinpoint, APC 3 time from second
joinpoint to 2013), AAPC average annual percentage change
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Fig. 3 Joinpoint regression analysis of age-standardized incidence of thyroid cancer for men, all ages 1970–2013. Incidence per 100,000
inhabitants for ICD-7 code 194 according to the Swedish Cancer Register (http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer)
Fig. 4 Joinpoint regression analysis of age-standardized incidence of thyroid cancer for men, aged 40–59 years 1970–2013. Incidence per 100,000
inhabitants for ICD-7 code 194 according to the Swedish Cancer Register (http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer)
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Fig. 5 Joinpoint regression analysis of age-standardized incidence of papillary thyroid cancer for women, all ages, 1993–2013. Incidence per
100,000 inhabitants for ICD-7 code 194; data obtained from the Swedish Cancer Register
Fig. 6 Joinpoint regression analysis of age-standardized incidence of papillary thyroid cancer for men, all ages, 1993–2013. Incidence per 100,000
inhabitants for ICD-7 code 194; data obtained from the Swedish Cancer Register
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was detected in 2007; 1993–2007 APC +2.90 % (95 %
CI +1.19, +4.64 %), 2007–2013 APC +11.11 % (95 %
CI +4.59, +18.03 %), and in women aged 60–79 years
in 2004; 1993–2004 APC −0.77 % (95 % CI −4.20,
+2.78 %), 2004–2013 APC +9.16 % (95 % CI +4.08,
+14.49 %). No joinpoint was detected in men in the
analyses of different age groups.
NORDCAN
According to NORDCAN, the incidence increased
statistically significantly in women during 1970–2013,
Table 3. Two joinpoints were found, 1977 and 2006.
Especially high APC was calculated during the time
from the second joinpoint in 2006 to 2013; +6.16 %
(95 % CI +3.94, +8.42 %). These results are displayed
in Fig. 7 with a more than 2-fold increased incidence
from 1970 to 2013.
Also in men the incidence increased during 1970–2013
with an AAPC of +1.40 % (95 % CI +0.88, +1.93 %),
Table 4. One joinpoint was detected in 2006 with an APC
during 2006–2013 of +6.84 % (95 % CI +3.69, +10.08 %).
As can be seen in Fig. 8, the incidence increased about 2-
fold in men as well during the time period.
Mobile phone calls
The number of total minutes of out-going mobile
phone calls in million minutes is available for the
Nordic countries for the time period 2001–2013 (PTS;
http://statistik.pts.se/PTSnordic/NordicBaltic2014/). In
Fig. 9 this data is shown in comparison with the join-
point regression analysis of incidence of thyroid cancer
in the Nordic countries for all ages during the same
time period. Clearly, with a lag time of some years after
the increasing number of out-going calls, the thyroid
cancer incidence is increasing.
Discussion
Main results
The main finding of this register based study was an in-
creasing incidence of thyroid cancer in Sweden during
the whole study period 1970–2013 in both women and
men, although not statistically significant in men. In
both genders the incidence increased during the more
recent study period, from 2001 in women and from
2005 in men. This increase was of similar magnitude
and statistically significant for both groups.
Based on NORDCAN, we analyzed the thyroid cancer
incidence during the same time period, 1970–2013, in
the Nordic countries. A statistically significant increase
in the incidence of thyroid cancer was seen throughout
the whole time period. The same joinpoint, 2006, was
found both for women and men. Interestingly, also the
APC during 2006–2013 was of a similar magnitude in
men and women. These results clearly show that the in-
creasing incidence is not gender specific, meaning that
women and men are equally affected and thus that the
increase is caused by similar agent(s) for both genders.
We obtained data from the Swedish Cancer Register
on different histopathology types of thyroid cancer for
the time period 1993–2013. A statistically significant in-
crease in incidence was found for papillary thyroid can-
cer, the type that is caused mainly by radiation [16]. The
increase was seen in both men and women, in the latter
with a joinpoint in 2006. The same joinpoint location
was found for thyroid cancer incidence in NORDCAN
in both men and women with a sharply increasing inci-
dence from that year. We also found a statistically sig-
nificant increase in incidence in men with mixed
papillary thyroid cancer using the Swedish Cancer Regis-
ter. These types are usually grouped together with the
papillary variant, although the Swedish Cancer Register
provided separate data and thus we could analyze these
groups separately. Our results clearly indicate that the
increasing incidence of thyroid cancer is mainly for the
papillary type and may be caused by radiation. Both ion-
izing and non-ionizing radiation should be considered.
Just recently, statistics from the Swedish Cancer
Register have been made official on all new cancer
cases for 2014 [22]. For thyroid cancer there is a con-
tinuous increase in incidence in 2014 compared to
2013, by 12.1 % for men, (from 3.3 to 3.7), and by
11.2 % for women, (from 8.9 to 9.9; age standardized
per 100,000 inhabitants).
Towards understanding the increasing incidence
Thyroid cancer incidence is increasing in many coun-
tries. This has largely been restricted to small tumors of
less than 2 cm with histopathological low aggressiveness
in some studies [23]. Overall incidence rates increased
during 1997–2008 in São Paulo, Brazil, especially the pap-
illary variant that is the most radiosensitive type. It was
concluded that the risk increase could not be only attrib-
uted to increased diagnostic procedures [24]. Increasing
Table 3 Joinpoint regression analysis of thyroid cancer incidence in women in the Nordic countries
ICD-10 Joinpoint location APC 1 (95 % CI) APC 2 (95 % CI) APC 3 (95 % CI) AAPC (95 % CI)
All women (n = 31,915) 1977; 2006 +4.00 (+1.83, +6.22) +0.47 (+0.20, +0.73) +6.16 (+3.94, +8.42) +1.94 (+1.44, +2.45)
NORDCAN data, time period 1970–2013, ICD-10 code C73 (http://www-dep.iarc.fr/NORDCAN/english/frame.asp)
APC annual percentage change (APC 1 time from 1970 to first joinpoint 1977, APC 2 time from first joinpoint to second joinpoint 2006, APC 3 time from second
joinpoint to 2013), AAPC average annual percentage change
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incidence, of especially the papillary type, was also re-
ported from the Netherlands [25] and Canada [26]. Better
access to healthcare and an increasing use of thyroid im-
aging causing ‘overdiagnosis’ has been suggested [27]. In a
series of 2,654 patients that underwent FDG-PET/CT, 34
patients had incidental thyroid lesion, including 11 can-
cer cases [28]. In fact, it has been discussed that in-
creasing diagnostic procedures may account for part of
the increasing incidence of thyroid cancer, so called
‘overdiagnosis’, but a true increase cannot be excluded
[27, 29].
A study of 18 cancer registers in the US showed an in-
creased incidence of all thyroid cancers between 2000–
2002 and 2010–2012 of 22.76 %. For papillary carcinoma
of the thyroid, the incidence increased by 173.86 %. The
increase included all sizes of papillary carcinoma, from
those under one centimeter to those over 4 cm [30]. The
incidence of thyroid cancer also increased during the
study period 1997 through 2011 in Korea [31]. Papillary
carcinoma showed the greatest increase with an APC of
+25.1 % (95 % CI +22.7, +27.5 %) in men, and an APC
of +23.7 % (95 % CI +22.9, +25.5 %) in women. It was
concluded that the increase was partly a screening effect,
but that among men born 1950 or later the exposure to
risk factors may have changed. The steeply increasing
incidence of thyroid cancer in Korea from early 2000
was also reported in other nationwide studies on cancer
statistics [32, 33].
The impact of diagnostic changes during 2003–2007
on the rise in thyroid cancer incidence was studied in
high-resource countries [29]. The study included the
Nordic countries. It was postulated that diagnostic
changes may account for ≥60 % of the cases in France,
USA, Australia and the Republic of Korea, about 50 % in
the Nordic countries and 30 % in Japan. It is noteworthy
that the main increase in Sweden was found after that
study period and thus cannot fully explain the results in
our joinpoint analysis.
Increased exposure to thyroid-specific environmental
carcinogens could be responsible, such as ionizing radi-
ation (mostly medical radiation), increased iodine intake
and chronic lymphocytic thyroiditis and environmental
pollutants such as nitrates, heavy metals and other com-
pounds largely used in the industrialized society [27].
Other factors that have been suggested include eating
habits, smoking, living in volcanic areas, xenobiotics and
viruses [34]. Certainly several of these factors are not rele-
vant to Sweden, i.e., living in a volcanic area. Smoking is
less common in Sweden now than previously [35] and
there is no information on a sudden change in eating
Table 4 Joinpoint regression analysis of thyroid cancer incidence in men in the Nordic countries
ICD-10 Joinpoint location APC 1 (95 % CI) APC 2 (95 % CI) AAPC (95 % CI)
All men (n = 11,513) 2006 +0.38 (+0.12, +0.63) +6.84 (+3.69, +10.08) +1.40 (+0.88, +1.93)
NORDCAN data, time period 1970–2013, ICD-10 code C73 (http://www-dep.iarc.fr/NORDCAN/english/frame.asp)
APC annual percentage change (APC 1 time from 1970 to joinpoint 2006, APC 2 time from joinpoint to 2013), AAPC average annual percentage change
Fig. 7 Joinpoint regression analysis of age-standardized incidence of thyroid cancer for women, all ages 1970–2013. Incidence per 100,000
inhabitants for ICD-10 code C73 in the Nordic countries according to NORDCAN (http://www-dep.iarc.fr/NORDCAN/english/frame.asp)
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Fig. 9 Number of out-going mobile phone minutes and incidence of thyroid cancer 2001–2013. Mobile phone minutes in millions in the Nordic
countries (http://statistik.pts.se/PTSnordic/NordicBaltic2014/) and incidence per 100,000 person-years for all ages 2001–2013 according to NORDCAN
(http://www-dep.iarc.fr/NORDCAN/english/frame.asp). Joinpoint regression analyses based on the time period 1970–2013
Fig. 8 Joinpoint regression analysis of age-standardized incidence of thyroid cancer for men, all ages 1970–2013. Incidence per 100,000
inhabitants for ICD-10 code C73 in the Nordic countries according to NORDCAN (http://www-dep.iarc.fr/NORDCAN/english/frame.asp)
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habits and exposure to xenobiotics and viruses. Increasing
use of CT scans including of the thorax, head and neck
might be of concern, especially since previous studies have
shown an increased risk for thyroid cancer [36, 37].
Ionizing radiation
Ionizing radiation is one established risk factor for thy-
roid cancer. Since the first correlation was reported in
the late 1940s, several studies have confirmed the associ-
ation. Especially studies of childhood X-ray treatment of
thymus and scalp ringworm have established radiation
as a risk factor, as well as among A-bomb survivors [37].
The dose-response curve seems to be linear and several
studies have indicated that the risk increase begins be-
tween 5 to 10 years after irradiation. There seems to be
a peak about 15–25 years post-irradiation, although the
increased risk continues for a long time, and is probably
life-long [38]. In fact, in Belarus and Ukraine an excess
of thyroid cancer incidence was observed within 3 years
after the Chernobyl accident in 1986 [39, 40]. Radio-
active elements were released from the Fukushima
Daiichi Nuclear Power Plant in March 2011. Using a la-
tency period of up to 4 years an excess of thyroid cancer
was reported in residents 18 years or younger [13]. The
minimum empirical latency (induction time) has been
reported to be 2.5 years in adults and 1 year for children
for radiation induced thyroid cancer [41]. Of the 87 op-
erated children in the Fukushima study papillary carcin-
oma of the thyroid was histologically confirmed in 83
[13]. Risk factors are younger age when exposed to radi-
ation and female gender. In experimental studies, syner-
gistic effects of radiation and chemicals that stimulate
thyroid tissue proliferation have been clearly shown [42].
Of special concern nowadays is the thyroid radiation
from CT medical examinations such as chest CT, whole
body trauma CT etc. Increasing trends in the number of
CT procedures in all Nordic countries were reported
during 1993 to 2010 (https://www.stralsakerhetsmyn-
digheten.se/Global/Pressmeddelanden/2012/justification_-
statement_nordic_2012.pdf). The number per 1,000 of
population increased from about 40 in the early 1990s to
100 or more at the end of the study period. It was
concluded that CT procedures contribute currently to
50–80 % of the total population dose from medical X-
ray. CT for pediatric use has increased and children are
more sensitive to radiation compared to adults. Su et al.
[36] concluded that especially chest CT-scans cause a
high thyroid dose and contribute to the lifetime attribut-
able risk of thyroid cancer.
Whole body PET-CT scanning is increasingly used in
medicine. From 2006 to 2013 the number of examinations
increased about 3 times in Sweden (http://www.skane.se/
Upload/Webbplatser/RCC/PET-CT-150522.pdf). It was
concluded that the examination is accomplished with sub-
stantial radiation dose and cancer risk including to the
thyroid gland [43].
Dental radiography is widely used in dental care, both
at the yearly to second yearly regular dental examination
and when needed in more urgent visits. A case-control
study from Kuwait showed a statistically significant dose
response pattern with an increasing trend in risk for thy-
roid cancer with increasing numbers of dental x-rays.
The association was essentially observed with papillary
carcinoma [44]. Using lead collars or aprons during each
dental x-ray can reduce the radiation dose, but these
were not commonly used in the Kuwait study [44].
Another study showed that more than 10 dental x-rays
increased the risk for thyroid cancer, especially the papil-
lary type [45]. An increased risk of thyroid cancer has
also been reported in female dentists and dental assis-
tants [9]. It should be noted that these are retrospective
studies. The radiation dose is nowadays lower for each
investigation, but on the contrary dental x-ray investiga-
tions are more frequently used than previously.
Radiofrequency radiation
One environmental factor that needs to be discussed in
this context is the public’s increased exposure to the ra-
diofrequency electromagnetic fields (RF-EMFs) due to
the use of mobile and cordless phones. With the de-
creased subscription cost and innovations in technology,
we have seen a large spread of mobile networking; mo-
bile phones are not only used to make phone calls but
also for using the internet. We have discussed that issue
in relation to the increasing rate of brain tumors in the
Swedish National Inpatient Register (IPR) and Causes of
Death Register (CDR) [46]. Moreover, there has been a
rapid increase in the use of wireless phones during the
last two decades. An estimate of 6.9 billion mobile
phone subscriptions worldwide was reported at the end
of 2014 by the International Telecommunication Union
[47]. Mobile phones were introduced in Sweden during
the early 1980s, but the real increase of the use has
taken place since the 1990s [48]. Desktop cordless
phones have been used since the end of the 1980s. There
are no official statistics on that use, but almost all desk-
top phones on the market are now of the wireless type.
While used, wireless phones emit RF-EMFs.
The brain is the primary target for RF-EMFs during
the use of wireless phones and an increased risk for
brain tumors has been found in several studies (for over-
views see [46, 49, 50]). The carcinogenic effect of RF-
EMFs was evaluated at a meeting in May 2011 at the
International Agency for Research on Cancer (IARC) at
WHO in Lyon. The Working Group categorized RF-
EMFs from mobile phones and from other devices that
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emit similar non-ionizing electromagnetic fields in the
frequency range 30 kHz – 300 GHz as Group 2B, i.e.,
‘possibly’ carcinogenic to humans [51, 52].
RF-EMF related organ-specific risk and exposure can
be calculated. The personal RF-EMF exposure consists
of far-field and near-field exposure. Far-field organ spe-
cific average (OSA) specific absorption rate (SAR) for
RF-EMF exposure was calculated in a study by Lauer et
al. [53]. The considered far-field sources were frequency
modulation (FM) radio stations, television broadcasting
stations, base stations for mobile phones and Digital En-
hanced Cordless Telecommunications (DECT), and
wireless fidelity (WiFi) hotspots. Besides the eye lens,
skin and testis, the thyroid gland was the organ with the
highest far-field OSA absorption. Also, near-field OSA
absorption caused by mobile phone and cordless phone
sources was calculated. The eye lens, skin and thyroid
gland were the organs with the highest exposure other
than the brain [53]. It can be summarized that both with
near-field and far-field exposure, the thyroid gland was
among the organs with the highest exposure. However,
the near-field SAR calculations have several limitations
[54]. Therefore, the mobile phone antenna location and
distance to the thyroid gland need to be observed more
closely.
The mobile phone handset antenna used to occupy a
quarter of the mobile phone’s size. With the emergence
of new communication protocols, new frequency bands
(e.g. GSM, UMTS, and LTE) required incorporating
more antennas into the mobile phone. This has in turn
increased the space the antennas occupy. It must be
noted that in order for the antenna to be efficient, a cer-
tain size is required. If an antenna size would be de-
creased, this would result in higher output power
requirements, which would also expose the user to
higher levels of radiation.
As pictured in Fig. 10, three developments in the
antenna design can be distinguished during the last
two decades. The second generation (2G) mobile
phones started in the 1990s with the external retract-
able monopole or helical antennas. The 2G GSM
band operated at 800/900 MHz frequency band, later
accompanied by 1,800 MHz band. Around the turn of
the millennium, the external antennas were starting
to disappear, replaced with new phone models with
internal planar or microstrip antennas. The first in-
ternal antenna was introduced in 1998 and the first
dual-band mobile phone, with the internal antenna,
was introduced on the market in 1999 [55]. The in-
ternal antennas were positioned at the top of the tele-
phone. With the emergence of the smartphones in
the mid and late 2000s, the internal antenna location
started to shift from the top of the phone to the bot-
tom. Currently, the majority of smartphone models
have their antenna positioned at the bottom of the
phone.
During the last decade, the smartphone popularity has
surpassed both the laptop and desktop computer sales in
many world markets. Smartphone sales have risen dra-
matically and replaced the basic feature phone market
[56]. 3G and 4G have become the new standards for mo-
bile communications in mature markets. Since the
launch of these new protocols the mobile data consump-
tion has been increasing, of which most takes place on
smartphones [57].
Compared to mobile feature phones, smartphones po-
tentially provide higher RF-EMF exposure. Smartphones
can connect to several networks: they come with built-in
communication protocols for 2G, 3G, 4G long-term evo-
lution (LTE), WiFi and Bluetooth for short distance and
near field communications (NFC).
Figure 11 provides mobile phone subscription trend
from 1996 to 2014 for Sweden, USA and South Korea
[58]. The World Bank’s indicator includes the number of
postpaid subscriptions, and the number of active prepaid
accounts; the indicator applies to all mobile cellular sub-
scriptions that offer voice communications [58].
Certainly, thyroid gland exposure to RF-EMFs has in-
creased, especially during the last one or two decades. It
should be further investigated as a cause of the increasing
incidence of thyroid cancer in the Nordic countries as well
as several other countries. The short induction time for
Fig. 10 Mobile phone antenna placements in regard to the thyroid gland
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thyroid cancer after exposure to ionizing radiation, as dis-
cussed above, should also be considered in that context.
RF-EMFs, thyroid hormones and morphology
Radiofrequency radiation at 2.45 GHz at a non-thermal
level modified the morphology of the thyroid gland. The
central and peripheral follicles presented increased size
and the thickness of peripheral septa decreased. Periph-
eral follicles increased in size with repeated exposure at
3 W power [59].
In another study on rats, whole body exposure to
900 MHz pulse-modulated RF radiation that was similar
to that emitted by the global system for mobile commu-
nications (GSM) mobile phones caused pathological
changes in the thyroid gland. The gland structure was
altered and caspase-dependent pathways of apoptosis
were enhanced [60].
Thyrocytes were exposed to RF-EMFs at mobile phone
frequency for 3 h in a study on human thyroid cells.
This led to increased proliferation of thyrocytes (p =
0.007). It was concluded that a proliferative effect was
seen that may link RF-EMFs with carcinogenesis [61].
The same research group used a signal generator expos-
ing the human thyroid primary cells at continuous wave
(CW) 900 MHz with maximum SAR of 0.170 W/kg. They
failed to find an association between this exposure and a
carcinogenic effect on thyroid cells [62].
Detrimental effects on the thyroid function with
altered levels of thyroid hormones in humans exposed to
RF-EMF from mobile phones [63], and also including
base stations [64] has been reported. In rats exposed to
900 MHz RF-EMF [65] and 2,450 MHz RF-EMF altered
thyroid levels were found [66]. Alternations of thyroid
stimulating hormone (TSH) levels were seen in one of
the rat studies with statistically significant decreased
levels [65], whereas the change was not statistically
significant in the other rat study [66]. In humans there
was a statistically significant increase of the TSH level
following mobile phone use [63]. Elevated levels of TSH
in humans is associated with thyroid growth and has
been postulated to increase the risk for thyroid cancer
[67, 68]. Certainly thyroid function deserves to be
further studied in person using wireless phones.
Strengths and limitations
Our study was based on official register data. The
completeness of registration of all cancer cases in the
Swedish Cancer Register has been questioned [69].
Fig. 11 Mobile phone subscriptions per 100 persons in South Korea, Sweden and United States from 1996–2014 [58]
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The underreporting to the register was mainly related
to a lack of cytology and histopathology for cancer
diagnosis. Especially visceral tumors were underre-
ported in a 2009 study [70]. In another study by in-
vestigating pancreatic and biliary tract cancer, a large
underreporting to the Swedish Cancer Register for
the years 1990–2009 was found [71]. Unfortunately
there exists no specific study about the completeness
of thyroid cancer registration.
The thyroid gland is easily accessed for biopsy. Benign
nodules are not reported to the Cancer Register, and for
confident diagnosis, cytology and/or histopathology is
needed. Based on the information published in “Cancer
Incidence in Sweden”, all thyroid cancer diagnoses
(100 %) were based on microscopic confirmations during
our study period, with a few exceptions when it was
based on 99 % microscopy.
In an ecological study there is no individual exposure
data set. Thus a causal association with any of the sug-
gested exposure types cannot be established. The results
of this paper suggest that further research is required.
Conclusions
This study has shown an increasing incidence of thyroid
cancer in Sweden and the Nordic countries. Better diagnos-
tic imaging cannot solely account for the increase.
Increased use of CT and PET-CT for medical examinations
has elevated the population’s exposure to the ionizing radi-
ation and should be considered as a risk factor. Exposure to
RF-EMFs also merits in-depth investigation. The design of
our study does not permit conclusions regarding causality.
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